Sinopharm shares phase 2 data on inactivated COVID-19 vaccine

Sinopharm shares phase 2 data on inactivated COVID-19 vaccine

Source: 
Fierce Biotech
snippet: 

Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus.